MRTX0902 is a novel small molecule drug that has been developed for the treatment of cancer. It belongs to the class of drugs known as inhibitors of the KRAS G12C protein, which plays a critical role in the growth and survival of many types of cancer cells.
Chemical Name: The chemical name of MRTX0902 is 4-((6-amino-5-((4-chlorophenyl)amino)-4-(pyridin-3-yl)pyridin-3-yl)thio)-N-(4-fluorophenyl)-1H-pyrazole-1-carboxamide.
Molecular Formula: The molecular formula of MRTX0902 is C26H19ClFN7OS.
Formula Weight: The molecular weight of MRTX0902 is 548.99 g/mol.
CAS No: The CAS number of MRTX0902 is 2654743-22-1.
Top Ten Keywords from Google and Synonyms:
Synonyms: MRTX0902 is also known by its brand name, which is "Adagrasib." Other synonyms include AMG 510, KRYSTAL-1, and an inhibitor of mutant KRAS(G12C).
Health Benefits of MRTX0902: MRTX0902 is still under development; hence, there are no established health benefits at present. However, preclinical studies have shown that it has significant potential in inhibiting tumor growth and proliferation in various cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer.
Potential Effects: Preclinical studies have demonstrated that MRTX0902 can selectively target the KRAS G12C protein, which is mutated in approximately 13% of all human cancers. By inhibiting this protein, MRTX0902 can prevent downstream signaling pathways involved in tumorigenesis, thus hindering tumor growth and progression. Additionally, it has shown promising results in combination with other targeted therapies, such as inhibitors of EGFR, in preclinical models of NSCLC.
Product Mechanism: MRTX0902 is a selective inhibitor of KRAS G12C, a mutation found in KRAS, a gene that plays a crucial role in cell growth and division. The KRAS G12C mutation is commonly found in many types of cancer and is associated with poor prognosis. By selectively inhibiting this mutation, MRTX0902 can prevent the downstream signaling pathways that promote tumor growth and proliferation.
Safety: MRTX0902 is still under investigation, and its safety profile is yet to be fully established. However, early-phase clinical trials have reported manageable toxicities, including nausea, vomiting, and diarrhea. As with any investigational drug, it is vital to carry out rigorous safety assessments before it becomes available for widespread use.
Side Effects: Common side effects reported in early-phase clinical trials include:
Dosing Information: MRTX0902 is currently being evaluated in Phase I/II clinical trials to determine the optimal dose and schedule for administration. The recommended dose and dosing regimen will be determined based on the outcome of these trials.
Conclusion: MRTX0902 is a promising new drug candidate for the treatment of cancer. By selectively targeting the KRAS G12C mutation, it can prevent the downstream signaling pathways that promote tumor growth and proliferation. Early-phase clinical trials have reported manageable toxicities, and ongoing clinical trials hope to determine its safety and efficacy further. If proven effective, MRTX0902 could offer a new option for patients with KRAS G12C-mutated cancers, which are associated with poor prognosis and limited treatment options. However, more extensive clinical trials are needed to establish its safety profile and determine the most effective dosing regimen.
